🇺🇸 FDA
Patent

US 11851653

Materials and methods for treatment of alpha-1 antitrypsin deficiency

granted A61KA61K31/7088A61K48/00

Quick answer

US patent 11851653 (Materials and methods for treatment of alpha-1 antitrypsin deficiency) held by CRISPR THERAPEUTICS AG expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/7088, A61K48/00, A61K9/0019, A61P